Elinzanetant, fezolinetant work against vasomotor symptoms

Both elinzanetant and fezolinetant are beneficial in the management of vasomotor symptoms in menopausal women, according to the results of a systematic review and meta-analysis. However, elinzanetant appears to exert greater effects on symptom frequency and severity, as well as sleep quality.

Researchers searched multiple online databases for randomized controlled trials (RCTs) in which fezolinetant and elinzanetant were compared with placebo for the treatment of vasomotor symptoms in menopausal women.

A total of seven RCTs involving 4,087 patients met the eligibility criteria and were included in the analysis. Pooled data showed that fezolinetant and elinzanetant were both associated with reduced vasomotor symptom frequency: fezolinetant 30 mg (mean difference [MD], 2.16, 95 percent confidence interval [CI], 1.54–2.79; I2=0 percent), fezolinetant 45 mg (MD, 2.54, 95 percent CI, 1.86–3.21; I2=0 percent), and elinzanetant 120 mg (MD, 2.99, 95 percent CI, 1.74–4.23; I2=0 percent).

Additionally, vasomotor symptom severity decreased with both drugs: fezolinetant 30 mg (MD, 0.20, 95 percent CI, 0.09–0.33; I2=0 percent), fezolinetant 45 mg (MD, 0.24, 95 percent CI, 0.13–0.34; I2=0 percent), and elinzanetant 120 mg (MD, 0.36, 95 percent CI, 0.26–0.46; I2=0 percent).

Sleep quality improvement was only observed with elinzanetant 120 mg (MD, 4.65, 95 percent CI, 3.73–5.56; I2=0 percent).

Compared with placebo, elinzanetant 120 mg was associated with a higher incidence of drug-related adverse events (20.75 percent vs 11.70 percent; risk ratio [RR], 0.57, 95 percent CI, 0.39–0.82; I2=19 percent) and headache (8.0 percent vs 2.54 percent; RR, 0.32, 95 percent CI, 0.16–0.64; I2=0 percent).